Orlando, FL, February 28, 2024 – ApiJect Systems, Corp., a medical technology public-benefit corporation, announced it has added product development capabilities, including Proof-of-Concept studies that use as little as 8 liters of vaccine or drug product to test compatibility in Blow-Fill-Seal (BFS) using ApiJect prefilled injector technology. Higher volumes may be needed based on the specific requirements of the drug product.
“We are delighted to make it easier than ever for pharmaceutical companies to test their drug product while realizing the benefits of the Prefilled ApiJect Injector,” said Bo Kowalczyk, Chief Commercial Officer, ApiJect. “With this added capability, biopharmaceutical development and manufacturing companies can provide us with a small amount of vaccine or drug product to test whether it can be reliably filled in BFS using ApiJect technology. We are excited to offer current and prospective customers Proof-of-Concept to “test drive” our technology.”
“New advances in Blow-Fill-Seal (BFS) aseptic packaging can improve both the cost and reliability of fill-finish for your sterile liquids,” said Nick Robinson, Senior Vice President, Distributed Manufacturing, ApiJect. “We use modern BFS processes to fill-finish injectable medicines and vaccines in single-dose prefilled formats at lower costs than traditional syringes and glass vials.”
Robinson continues, “The ability to offer Proof-of-Concept studies is an important milestone for our team. We can prove to companies that BFS can help injectables reliably reach more patients in more markets in a prefilled, ready-to-use format.”
Dave Boerschel, Program Director, BFS will be on hand during DCAT Week to handle product development and Proof-of-Concept questions. Dave Boerschel has extensive expertise in BFS development projects and over the years, has identified and worked through countless challenges relative to costs, timings, and design concerns. To schedule an onsite meeting, please click here.
This innovation was achieved by ApiJect engineers at the company’s Technology Development Center in the greater Orlando, FL area. This growing 16,000+ sq. ft. facility features a range of BFS machines and prototype mold design and making equipment, helping pharmaceutical companies better understand how the BFS advanced aseptic process, when combined with ApiJect technology, can enable more of their drug products to be offered in a prefilled format.
ABOUT APIJECT SYSTEMS, CORP.
ApiJect Systems, Corp. is a public-benefit medical technology company working to bring prefilled, single-dose injections to more people in every market around the world. The ApiJect Platform enables pharmaceutical and biotech companies to design scalable prefilled injectors and efficiently fill-finish them with their injectable drug products. This can be done either on one of their own ApiJect-licensed Blow-Fill-Seal packaging lines or at one of our world-class manufacturing partners.
Learn more at www.apiject.com or contact Kate Scott at [email protected].
